Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends
Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends
TUESDAY, April 5 (HealthDay News) — In the latest analysis from the Women’s Health Initiative (WHI) study, researchers report that risks to postmenopausal women who were taking estrogen-only hormone therapy faded rapidly after they ended the treatment.
Read more on BusinessWeek
Categories: Breast Cancer Information Tags: after, Ends, estrogen, Fade, Hormone, Risks, Seen, Therapy, Treatment
You Docs: There’s still a good chance that hormone therapy can help you
You Docs: There’s still a good chance that hormone therapy can help you
What are the newer, safer forms? Bioidentical estrogen (estradiol) and micronized progesterone, which doesn’t block estrogen’s artery-pampering effects.
Read more on The Oregonian
Ending hormone therapy doesn’t cut breast-cancer risk, study says
Ending hormone therapy doesn’t cut breast-cancer risk, study says
Estrogen-plus-progestin hormone replacement therapy increases the risk of breast cancer in postmenopausal women. Now, a longer-term study of the problem shows the higher risk of breast cancer continues among women who took hormones but stopped, that the cancer in these women may be more advanced and that the likelihood of dying of breast cancer is increased.
Read more on Seattle Times
Categories: Breast Cancer Risks Tags: breastcancer, doesn't, ending, Hormone, Risk, says, Study, Therapy
Hormone therapy linked to more aggressive, deadlier breast cancers
Hormone therapy linked to more aggressive, deadlier breast cancers
Latest results from the Women’s Health Initiative, which included thousands of San Antonio women, finds the news about hormone treatment even bleaker than before.
Read more on San Antonio Express-News
Categories: Breast Cancer Questions & Answers Tags: aggressive, breast, cancers, deadlier, Hormone, Linked, more, Therapy
Hormone shot to fight breast cancer
Hormone shot to fight breast cancer
A Rs-75 injection increases the chances of survival for patients of breast cancer, a study conducted by the Tata Memorial Centre, Parel, has found. The cancer research institute carried out the study over a period of 12 years, involving 1,000 patients.
Read more on Hindustan Times
